Skip to main content

Table 1 Characteristics and genomic applications of tumors and their respective derived preclinical models

From: From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models

Pz code

Gender

Age at diagnosis (months)

Histopathologic classification of the tumor

INRG-SS Stage

Immunohistochemistry

Flow Cytometry

WES-g

WES-t

CGP

RNAseq

MYCN

CD45

CD56

TH

Phox-2B

S100

CD45

CD56

GD2

B7-H3

NCL

yes (y)

yes (y)

yes (y)

yes (y)

pz#0

M

35

NB, Schwannian-stroma poor, poorly differentiated

M

No ampl

 + 

 + 

 + 

 + 

NP

NP

NP

NP

NP

y

y

  

pz#1

M

41

NB, Schwannian-stroma poor, poorly differentiated

M

NP

 + 

 + 

 + 

 + 

NP

NP

NP

NP

NP

NP

 

y

  

Pz#2

F

8

NB, Schwannian-stroma poor, poorly differentiated

L2

No ampl

 + 

 + 

 + 

 + 

NP

NP

NP

NP

NP

NP

y

y

 

y

Pz#2bis

    

No ampl

NP

NP

NP

NP

NP

 + 

NP

 + 

 

y

  

Pz#3

M

46

NB, Schwannian-stroma poor, undifferentiated

M

Ampl

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 + 

y

y

 

y

PDX#3-P1

  

NB, Schwannian-stroma poor, undifferentiated

 

Ampl

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 

y

 

y

PDX#3-P2

  

NB, Schwannian-stroma poor, undifferentiated

 

Ampl

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 

y

 

y

PDX#3-P2-3D

    

NP

NP

NP

NP

NP

NP

 + 

 + 

 + 

NP

 

y

  

Pz#4

F

198

NB, Schwannian-stroma poor, undifferentiated

M

No ampl

 + 

 + 

 + 

NP

 + 

 + 

 + 

 + 

 + 

y

y

 

y

PDX#4-P1

  

NB, Schwannian-stroma poor, undifferentiated

 

No ampl

 + 

 + 

 + 

 + 

 + 

 + 

 

y

 

y

PDX#4-P2

  

NB, Schwannian-stroma poor, undifferentiated

 

No ampl

 + 

 + 

 + 

 + 

 + 

 + 

 

y

 

y

PDX#4-P2-3D

    

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

 

y

  

Pz#5

M

49

NB, Schwannian-stroma poor, undifferentiated

M

No ampl GNE

 + 

NP

 + 

 + 

NP

NP

NP

NP

NP

NP

y

y

  

PDX#5-P1

  

NB, Schwannian-stroma poor, undifferentiated

 

No ampl GNE

 + 

 + 

 + 

NP

NP

NP

NP

NP

 

y

  

PDX#5-P2

  

NB, Schwannian-stroma poor, poorly differentiated

 

gain

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 

y

  

PDX#5-P2-3D

    

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

    

Pz#6

M

45

NE

L2

No ampl

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

y

y

  

Pz#7

M

172

NB, Schwannian-stroma poor, undifferentiated

L1

No ampl

 + 

 + 

 + 

 ± 

NP

NP

NP

NP

NP

y

y

 

y

Pz#8

F

89

NB, Schwannian-stroma poor, undifferentiated

L2

No ampl

 ± 

 + 

 + 

NE

 + 

 + 

 + 

 + 

 + 

y

y

 

y

PDX#8-P1

  

NB, Schwannian-stroma poor, undifferentiated

 

No ampl

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 

y

 

y

PDX#8-P2

  

NB, Schwannian-stroma poor, undifferentiated

 

No ampl

 + 

 + 

 + 

 + 

 + 

 + 

 + 

 

y

  

PDX#8-P2-3D

    

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

 

y

  

Pz#9

M

65

NB, Schwannian-stroma poor, undifferentiated

M

No ampl

 + 

 + 

 + 

NP

NP

NP

NP

NP

y

y

  

Pz#10

F

51

NB, Schwannian-stroma poor, poorly differentiated

M

No ampl

 + 

 + 

 + 

 + 

NP

NP

NP

NP

NP

^y (CGP)

 

y

 

Pz#11

F

1

NB, Schwannian-stroma poor, poorly differentiated

L1

No ampl

 + 

 + 

 + 

 ± 

NP

NP

NP

NP

NP

y

y

 

y

Pz#14

F

101

NB, Schwannian-stroma poor, poorly differentiated

L1

No ampl

 + 

 + 

 ± 

 + 

NP

NP

NP

NP

NP

y

y

 

y

Pz#C

F

22

 

M

Ampl

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 + 

y

y

 

y

Pz#C-3D

    

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

NP

    

CPDX#C-P1

  

NB, Schwannian-stroma poor, undifferentiated

 

Ampl

 + 

 + 

 + 

 + 

 + 

 + 

 ± 

 

y

 

y

CPDX#C-P1-3D

    

NP

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

    

CPDX#C-P2

  

NB, Schwannian-stroma poor, undifferentiated

 

Ampl

 + 

 + 

 + 

 + 

 + 

 + 

 ± 

 

y

  

CPDX#C-P2-3D

    

NP

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 

y

  

Pz#D

M

68

 

M

NP

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 + 

y

y

  

Pz#F

F

39

 

M

No ampl

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 ± 

y

 

y

 

Pz#H

M

39

 

M

Gain

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 ± 

y

 

y

y

Pz#I

F

27

 

M

Ampl

NP

NP

NP

NP

NP

 + 

 + 

 + 

 + 

 ± 

y

 

y

 
  1. All tumors derived from patients at relapsed except for Pz#C
  2. In bold bone marrow-infiltrating NB cells
  3. NB neuroblastoma, Pz patient, PDX Patient-Derived Xenografts, CPDX Cell Patient-Derived Xenografts, 3D tumor-spheres, M male, F female, ampl amplified, no ampl not amplified, GNE gain not evaluable, NP not performed, NE not evaluable
  4.  +  positive, − negative, ±  slightly positive, WES-g whole exome sequencing of germline DNA, WES-t whole exome sequencing of tumor DNA, CGP cancer gene panel
  5. ^CPG of germline DNA has been performed for the Pz#10